2 results match your criteria: "Misawa Municipal Misawa Hospital[Affiliation]"
Article Synopsis
- The study aims to assess the safety and effectiveness of FOLFIRI combined with aflibercept (AFL) as a second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are resistant to prior treatments involving anti-EGFR antibodies.
- The main goal is to evaluate the 6-month progression-free survival (PFS) rate, with secondary goals including overall survival, response rates, and potential adverse effects, based on a sample size of 41 participants.
- This research is necessary due to the lack of clinical trial data specifically for mCRC patients who have failed anti-EGFR therapy, highlighting the need for a prospective study to fill this knowledge gap.
Genetic analyses of oculocutaneous albinism types 2 and 4 with eight novel mutations.
J Dermatol Sci
February 2016
Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.